Gilder Gagnon Howe & Co’s MedTech Acquisition Corporation Unit MTACU Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio MTACU Stock Details MTACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-310,224	Closed	-$3.11M	–	362
2021 Q4	$3.11M	Sell	310,224 -457	-0.1%	-$4.68K	0.02%	248
2021 Q3	$3.15M	Buy	+310,681	New	+$3.13M	0.02%	284

Other funds holding MTACU

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

ICMH

Integrity Capital Management (HK) Central, Hong Kong $64K AUM

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Gilder Gagnon Howe & Co's MTACU Position: Q1 2022 in Review

Gilder Gagnon Howe & Co sold out of MedTech Acquisition Corporation Unit (MTACU) in Q1 2022, closing a stake of 310,224 shares — an estimated $3.11M sold.

Gilder Gagnon Howe & Co first reported a position in MTACU in Q3 2021 and held it in 2 quarters. The position peaked at $3.15M in Q3 2021. 5 funds tracked by Wall St. Rank hold MTACU as of Q1 2022.

Gilder Gagnon Howe & Co reported no remaining MedTech Acquisition Corporation Unit position as of Q1 2022 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 310,224 MedTech Acquisition Corporation Unit shares in Q1 2022, an estimated $3.11M.
Gilder Gagnon Howe & Co first reported a position in MedTech Acquisition Corporation Unit in Q3 2021 and held it in 2 quarters.
Gilder Gagnon Howe & Co's MedTech Acquisition Corporation Unit position peaked at $3.15M in Q3 2021.
5 funds tracked by Wall St. Rank held MedTech Acquisition Corporation Unit as of Q1 2022.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2022, filed 16 May 2022.